Valuation : Lantheus Holdings, Inc.

Market Cap 659.06Cr 566.99Cr 533.34Cr 486.7Cr 910.35Cr 62TCr 912.92Cr 6.31TCr 2.44TCr 32TCr 2.47TCr 2.42TCr 1,01700Cr P/E 2026 *
21.4x
P/E 2027 * 18.1x
Enterprise Value 637.2Cr 548.19Cr 515.65Cr 470.55Cr 880.16Cr 60TCr 882.64Cr 6.11TCr 2.36TCr 31TCr 2.39TCr 2.34TCr 98TCr EV / Sales 2026 *
4.25x
EV / Sales 2027 * 3.62x
Free-Float
88.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.01%
1 week+0.20%
Current month+0.01%
1 month-0.10%
3 months-0.01%
6 months+39.15%
Current year+51.72%
1 week 100.54
Extreme 100.5372
101.43
1 month 99.97
Extreme 99.97
101.43
Current year 63.37
Extreme 63.37
111.86
1 year 49.67
Extreme 49.67
111.86
3 years 47.25
Extreme 47.25
126.89
5 years 22.2
Extreme 22.2
126.89
10 years 7.18
Extreme 7.18
126.89
Manager TitleAgeSince
Chief Executive Officer 66 01/01/2026
Director of Finance/CFO 60 21/09/2018
Chief Tech/Sci/R&D Officer 64 01/08/2025
Director TitleAgeSince
Director/Board Member 80 01/05/2012
Chairman 66 01/03/2024
Director/Board Member 61 01/01/2017
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Tax

Chief Financial Officer

-721 0.0011%
17/08/26 Tax

Controller/Auditor

-463 0.0007%
17/08/26 Tax

Chief Technology Officer

-2,536 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-0.01%+0.20%+84.42%+51.31% 659.06Cr
+0.23%-0.06%+168.44%+369.49% 2.17TCr
-2.29%-3.59%-38.67%-20.92% 1.02TCr
-0.90%+1.80%+348.78%+20.09% 816.27Cr
-0.99%-2.18%-28.06% - 708.47Cr
-1.11%-2.36%-21.62%-13.93% 602.72Cr
-1.75%-3.37%-10.08%-20.68% 433.5Cr
+2.96%+2.56%+80.17%+92.05% 422.46Cr
-1.43%-1.69%-19.83%-30.01% 280.71Cr
-2.87%+2.96% - - 138.6Cr
Average -0.82%+0.21%+62.62%+55.93% 724.34Cr
Weighted average by Cap. -0.59%-0.17%+92.46%+131.70%

Financials

2026 *2027 *
Net sales 149.94Cr 128.99Cr 121.34Cr 110.73Cr 207.11Cr 14TCr 207.69Cr 1.44TCr 555.45Cr 7.26TCr 563.05Cr 550.67Cr 23TCr 165.36Cr 142.26Cr 133.82Cr 122.12Cr 228.41Cr 16TCr 229.06Cr 1.58TCr 612.58Cr 8.01TCr 620.96Cr 607.3Cr 26TCr
Net income 32Cr 27Cr 26Cr 24Cr 44Cr 3.02TCr 44Cr 306.15Cr 118.37Cr 1.55TCr 119.99Cr 117.35Cr 4.93TCr 39Cr 34Cr 32Cr 29Cr 54Cr 3.71TCr 54Cr 375.85Cr 145.32Cr 1.9TCr 147.31Cr 144.07Cr 6.05TCr
Net Debt -22Cr -19Cr -18Cr -16Cr -30Cr -2.07TCr -30Cr -209.43Cr -81Cr -1.06TCr -82Cr -80Cr -3.37TCr -60Cr -51Cr -48Cr -44Cr -83Cr -5.65TCr -83Cr -572.67Cr -221.42Cr -2.9TCr -224.45Cr -219.52Cr -9.22TCr
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
Employees
1,193
Date Price Change Volume
04/26/04 $100.97 -0.01% 8,59,896
03/26/03 $100.98 +0.17% 7,37,070
02/26/02 $100.81 -0.07% 7,80,327
01/26/01 $100.88 -0.08% 13,80,180
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
100.97USD
Average target price
107.74USD
Spread / Average Target
+6.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LNTH Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!